JP2003505343A - ボツリヌス神経毒を含む治療薬 - Google Patents

ボツリヌス神経毒を含む治療薬

Info

Publication number
JP2003505343A
JP2003505343A JP2001501237A JP2001501237A JP2003505343A JP 2003505343 A JP2003505343 A JP 2003505343A JP 2001501237 A JP2001501237 A JP 2001501237A JP 2001501237 A JP2001501237 A JP 2001501237A JP 2003505343 A JP2003505343 A JP 2003505343A
Authority
JP
Japan
Prior art keywords
neurotoxin
botulinum
neurotoxins
mixture
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001501237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003505343A5 (https=
Inventor
ビガルケ・ハンス
フレヴェルト・ユルゲン
Original Assignee
メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003505343(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー filed Critical メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー
Publication of JP2003505343A publication Critical patent/JP2003505343A/ja
Publication of JP2003505343A5 publication Critical patent/JP2003505343A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001501237A 1999-06-07 2000-05-26 ボツリヌス神経毒を含む治療薬 Pending JP2003505343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19925739A DE19925739A1 (de) 1999-06-07 1999-06-07 Therapeutikum mit einem Botulinum-Neurotoxin
DE19925739.6 1999-06-07
PCT/DE2000/001777 WO2000074703A2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007130686A Division JP2007238627A (ja) 1999-06-07 2007-05-16 ボツリヌス神経毒を含む治療薬

Publications (2)

Publication Number Publication Date
JP2003505343A true JP2003505343A (ja) 2003-02-12
JP2003505343A5 JP2003505343A5 (https=) 2007-06-28

Family

ID=7910318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001501237A Pending JP2003505343A (ja) 1999-06-07 2000-05-26 ボツリヌス神経毒を含む治療薬
JP2007130686A Withdrawn JP2007238627A (ja) 1999-06-07 2007-05-16 ボツリヌス神経毒を含む治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007130686A Withdrawn JP2007238627A (ja) 1999-06-07 2007-05-16 ボツリヌス神経毒を含む治療薬

Country Status (26)

Country Link
US (3) US7964199B1 (https=)
EP (1) EP1185291B2 (https=)
JP (2) JP2003505343A (https=)
KR (1) KR100466407B1 (https=)
CN (2) CN100389820C (https=)
AR (1) AR024306A1 (https=)
AT (1) ATE258803T1 (https=)
AU (1) AU774590B2 (https=)
CA (1) CA2376193C (https=)
CO (1) CO5170431A1 (https=)
CZ (1) CZ20014351A3 (https=)
DE (3) DE19925739A1 (https=)
DK (1) DK1185291T3 (https=)
EA (1) EA004202B1 (https=)
ES (1) ES2215056T5 (https=)
GE (1) GEP20043200B (https=)
HU (1) HUP0201530A3 (https=)
IL (2) IL146974A0 (https=)
MX (1) MXPA01012540A (https=)
NO (1) NO20015964L (https=)
PL (1) PL198958B1 (https=)
PT (1) PT1185291E (https=)
TW (1) TWI251492B (https=)
UA (1) UA72253C2 (https=)
WO (1) WO2000074703A2 (https=)
ZA (1) ZA200110074B (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
JP2010529000A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法
JP2011506511A (ja) * 2007-12-21 2011-03-03 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
JPWO2009123174A1 (ja) * 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
JP2013508388A (ja) * 2009-10-21 2013-03-07 ルバンス セラピュティックス インク． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
JP2013100304A (ja) * 2008-03-14 2013-05-23 Allergan Inc 免疫基盤ボツリヌス毒素血清ａ型活性アッセイ
JP2016527257A (ja) * 2013-07-30 2016-09-08 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素の高純度神経毒成分の製造方法とその使用
JP2024522931A (ja) * 2021-07-08 2024-06-21 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20050163809A1 (en) * 2002-03-29 2005-07-28 Ryuji Kaji Remedy for hypermyotonia
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
EP2272340B1 (en) * 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
BRPI0508410B8 (pt) 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2266599B1 (en) 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
AU2005288758A1 (en) * 2004-09-27 2006-04-06 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in tissue healing
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
ES2509872T3 (es) * 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
KR101176248B1 (ko) * 2005-06-17 2012-08-22 메르츠 파마 게엠베하 운트 코. 카가아 발효에 의해 생물학적 활성 화합물을 제조하기 위한 장치및 방법
CN103126971A (zh) 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
DE102007038015A1 (de) 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
US8540987B2 (en) * 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20110060903A (ko) 2008-08-29 2011-06-08 메르츠 파마 게엠베하 운트 코. 카가아 지속성이 변경된 클로스트리듐 신경독
EP2161033B1 (en) 2008-09-09 2013-05-01 Susanne Dr. Grafe Botulinum toxin to introduce temporal infertiliy in a vertebrate (e.g. human)
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
BR112013033363A2 (pt) * 2011-06-27 2017-01-31 Duck Kim Sang composição farmacêutica para tratamento de cicatrizes na pele, e método para tratar cicatrizes na pele usando a mesma
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3285800B1 (en) * 2015-04-24 2019-09-18 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINARY NEUROTOXINS FOR USE IN THERAPY
AU2018237799B2 (en) 2017-03-24 2024-11-14 Merz Pharma Gmbh & Co. Kgaa Improved use of botulinum neurotoxin in the treatment of sialorrhea
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
EP3860640A1 (en) 2018-10-02 2021-08-11 Merz Pharma GmbH & Co. KGaA Novel uses of botulinum neurotoxin for treating lipoedema
KR20210130711A (ko) 2019-02-21 2021-11-01 메르츠 파마 게엠베하 운트 코. 카가아 진전의 치료를 위한 보툴리눔 신경독의 신규 용도
BR112022023413A2 (pt) 2020-06-05 2022-12-20 Merz Pharma Gmbh & Co Kgaa Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法
AR131172A1 (es) 2022-11-28 2025-02-19 Merz Pharma Gmbh & Co Kgaa Inyección de toxina botulínica en el platisma para el rejuvenecimiento del rostro inferior y del cuello
IL320937A (en) 2022-11-28 2025-07-01 Merz Pharma Gmbh & Co Kgaa High-concentration botulinum toxin treatment for neck rejuvenation
WO2024194181A1 (en) 2023-03-20 2024-09-26 Merz Therapeutics GmbH Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient
WO2024240868A1 (en) 2023-05-23 2024-11-28 Merz Therapeutics GmbH Botulinum toxin for treating peripheral neuropathic pain
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286405T1 (de) 1993-05-14 2005-01-15 Stephen S Arnon Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
DE69428813T2 (de) 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0758900B1 (en) 1994-05-09 2002-04-10 BINDER, William J. Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
EP0773788B1 (en) * 1995-06-06 2003-05-07 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
JP2010529000A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌス毒素の神経毒成分をベースにした温度に安定な筋弛緩薬の提供方法
JP2010528999A (ja) * 2007-06-01 2010-08-26 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー ボツリヌストキシンの神経毒成分に基づいた、温度安定な筋弛緩薬を固体形態で供給する方法
JP2011506511A (ja) * 2007-12-21 2011-03-03 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用
JP2013100304A (ja) * 2008-03-14 2013-05-23 Allergan Inc 免疫基盤ボツリヌス毒素血清ａ型活性アッセイ
JPWO2009123174A1 (ja) * 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
US9623075B2 (en) 2008-03-31 2017-04-18 The Chemo-Sero Therapeutic Research Institute Type A2 botulinum toxin preparation
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
JP2013508388A (ja) * 2009-10-21 2013-03-07 ルバンス セラピュティックス インク． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
US9469849B2 (en) 2009-10-21 2016-10-18 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
US11466262B2 (en) 2009-10-21 2022-10-11 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
JP2016527257A (ja) * 2013-07-30 2016-09-08 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素の高純度神経毒成分の製造方法とその使用
JP2024522931A (ja) * 2021-07-08 2024-06-21 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法
JP7680099B2 (ja) 2021-07-08 2025-05-20 ファルマ リサーチ バイオ シーオー・，エルティーディー． 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法

Also Published As

Publication number Publication date
DE19925739A1 (de) 2000-12-21
CN100389820C (zh) 2008-05-28
AR024306A1 (es) 2002-09-25
US7964199B1 (en) 2011-06-21
JP2007238627A (ja) 2007-09-20
EA200200017A1 (ru) 2002-06-27
EP1185291B2 (de) 2010-10-27
PL352468A1 (en) 2003-08-25
WO2000074703B1 (de) 2001-06-07
ES2215056T3 (es) 2004-10-01
US20110217287A1 (en) 2011-09-08
WO2000074703A3 (de) 2001-04-26
CZ20014351A3 (cs) 2002-06-12
UA72253C2 (uk) 2005-02-15
WO2000074703A2 (de) 2000-12-14
GEP20043200B (en) 2004-03-25
PL198958B1 (pl) 2008-08-29
EP1185291B1 (de) 2004-02-04
HUP0201530A3 (en) 2002-10-28
DK1185291T3 (da) 2004-04-05
ZA200110074B (en) 2003-03-06
IL146974A (en) 2007-05-15
NO20015964D0 (no) 2001-12-06
HUP0201530A2 (en) 2002-09-28
CO5170431A1 (es) 2002-06-27
NO20015964L (no) 2002-01-30
MXPA01012540A (es) 2004-09-27
ES2215056T5 (es) 2011-03-15
HK1047403A1 (zh) 2003-02-21
AU774590B2 (en) 2004-07-01
US8398998B2 (en) 2013-03-19
PT1185291E (pt) 2004-06-30
KR20020008214A (ko) 2002-01-29
CA2376193A1 (en) 2000-12-14
CA2376193C (en) 2008-09-16
KR100466407B1 (ko) 2005-01-27
IL146974A0 (en) 2002-08-14
EP1185291A2 (de) 2002-03-13
CN101062009A (zh) 2007-10-31
TWI251492B (en) 2006-03-21
CN1354670A (zh) 2002-06-19
DE10081516D2 (de) 2001-09-13
DE50005208D1 (de) 2004-03-11
ATE258803T1 (de) 2004-02-15
EA004202B1 (ru) 2004-02-26
US20120088732A1 (en) 2012-04-12
AU5804700A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
JP2003505343A (ja) ボツリヌス神経毒を含む治療薬
AU2020440362B2 (en) Botulinum toxin type A complex, and formulation thereof and usage method therefor
EP1491205A1 (en) Remedy for hypermyotonia
TWI739368B (zh) A型肉毒桿菌毒素複合物、其配製劑和使用方法
HK1047403B (en) Therapeutic agent comprising a botulinum neurotoxin
HK1110204A (en) Therapeutic agent comprising a botulinum neurotoxin
HK40085605A (en) Botulinum toxin type a complex, and formulation thereof and usage method therefor
CN117693366A (zh) 用于治疗上肢痉挛的方法和组合物
DE20023785U1 (de) Therapeutikum mit einem Botulinum-Neurotoxin
HK40063817A (en) Botulinum toxin type a complex, and formulation thereof and usage method therefor
COLVILLE THE INTERACTION OF TETANUS TOXIN
HK1040927A1 (zh) 稳定的肉毒毒素液体制剂
HK1040927B (en) Stable liquid formulations of botulinum toxin

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070116

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070521

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070608

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527